Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Lumosa Therapeutics Statistics

Total Valuation

TPEX:6535 has a market cap or net worth of TWD 31.76 billion. The enterprise value is 30.75 billion.

Market Cap	31.76B
Enterprise Value	30.75B

Important Dates

The last earnings date was Monday, November 10, 2025.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

TPEX:6535 has 168.46 million shares outstanding. The number of shares has increased by 1.84% in one year.

Current Share Class	168.46M
Shares Outstanding	168.46M
Shares Change (YoY)	+1.84%
Shares Change (QoQ)	-0.11%
Owned by Insiders (%)	1.91%
Owned by Institutions (%)	6.83%
Float	88.25M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	852.46
PB Ratio	19.49
P/TBV Ratio	19.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-48.92
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-73.21

Financial Position

The company has a current ratio of 10.00, with a Debt / Equity ratio of 0.01.

Current Ratio	10.00
Quick Ratio	8.68
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-1,994.03

Financial Efficiency

Return on equity (ROE) is -42.38% and return on invested capital (ROIC) is -17.29%.

Return on Equity (ROE)	-42.38%
Return on Assets (ROA)	-15.70%
Return on Invested Capital (ROIC)	-17.29%
Return on Capital Employed (ROCE)	-25.77%
Revenue Per Employee	866,302
Profits Per Employee	-14.62M
Employee Count	43
Asset Turnover	0.02
Inventory Turnover	0.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.85% in the last 52 weeks. The beta is 0.11, so TPEX:6535's price volatility has been lower than the market average.

Beta (5Y)	0.11
52-Week Price Change	-47.85%
50-Day Moving Average	264.53
200-Day Moving Average	198.07
Relative Strength Index (RSI)	31.29
Average Volume (20 Days)	832,082

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:6535 had revenue of TWD 37.25 million and -628.59 million in losses. Loss per share was -3.80.

Revenue	37.25M
Gross Profit	18.34M
Operating Income	-420.74M
Pretax Income	-640.26M
Net Income	-628.59M
EBITDA	-416.52M
EBIT	-420.74M
Loss Per Share	-3.80

Balance Sheet

The company has 1.03 billion in cash and 10.33 million in debt, giving a net cash position of 1.02 billion or 6.03 per share.

Cash & Cash Equivalents	1.03B
Total Debt	10.33M
Net Cash	1.02B
Net Cash Per Share	6.03
Equity (Book Value)	1.63B
Book Value Per Share	9.60
Working Capital	1.08B

Cash Flow

In the last 12 months, operating cash flow was -419.38 million and capital expenditures -668,000, giving a free cash flow of -420.05 million.

Operating Cash Flow	-419.38M
Capital Expenditures	-668,000
Free Cash Flow	-420.05M
FCF Per Share	-2.49

Margins

Gross Margin	49.22%
Operating Margin	-1,129.47%
Pretax Margin	-1,718.78%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TPEX:6535 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.84%
Shareholder Yield	-1.84%
Earnings Yield	-1.98%
FCF Yield	-1.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:6535 has an Altman Z-Score of 186.92 and a Piotroski F-Score of 2.

Altman Z-Score	186.92
Piotroski F-Score	2